<code id='F16FA93BB1'></code><style id='F16FA93BB1'></style>
    • <acronym id='F16FA93BB1'></acronym>
      <center id='F16FA93BB1'><center id='F16FA93BB1'><tfoot id='F16FA93BB1'></tfoot></center><abbr id='F16FA93BB1'><dir id='F16FA93BB1'><tfoot id='F16FA93BB1'></tfoot><noframes id='F16FA93BB1'>

    • <optgroup id='F16FA93BB1'><strike id='F16FA93BB1'><sup id='F16FA93BB1'></sup></strike><code id='F16FA93BB1'></code></optgroup>
        1. <b id='F16FA93BB1'><label id='F16FA93BB1'><select id='F16FA93BB1'><dt id='F16FA93BB1'><span id='F16FA93BB1'></span></dt></select></label></b><u id='F16FA93BB1'></u>
          <i id='F16FA93BB1'><strike id='F16FA93BB1'><tt id='F16FA93BB1'><pre id='F16FA93BB1'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:knowledge    Page View:85875
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In